Catalent snaps up Aptuit's trial supplies ops for $410M

Pumping up its clinical trial services muscle, Catalent Pharma announced it is buying Aptuit's clinical trial supply business for $410 million in cash. Aptuit, a contract research and manufacturing company which purchased GSK's R&D center in Verona, Italy last year, says the deal will allow the company to focus more closely on building its global discovery and development services operations. "This transaction builds important expertise, scale and capability for our development and clinical services business to better meet our customers' needs globally," said Catalent CEO John Chiminski in a statement. "This transaction also strengthens Catalent's global leadership in development solutions and advanced delivery technologies for drugs and biologics." Catalent release

Suggested Articles

A Roche compound that was designed to treat rheumatoid arthritis could improve the heart's ability to repair itself, a Vanderbilt team found.

After a whirlwind year and two quick-fire raises, cancer startup Black Diamond Therapeutics has nabbed Yumanity, Merck KGaA and SR One veterans to help head up…

In this week's EuroBiotech Report, Lundbeck inks $2 billion Alder buyout, Euro biotechs raise cash and blast rocks Russian smallpox lab.